http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101888744-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2016-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101888744-B1 |
| titleOfInvention | Method of providing the information for selecting the drugs for treating EML4-ALK positive non-small-cell lung cancer resistant to ALK inhibitors |
| abstract | The present invention provides a biomarker for providing information on drug selection in the treatment of EML4-ALK-positive non-small cell lung cancer resistant to an ALK inhibitor, which comprises an EML4-ALK-positive non-small cell lung cancer Compositions and kits for detecting the level of expression of miR-34a and / or miR-449 to provide information on drug selection in the treatment of < RTI ID = 0.0 > miR-34a < / RTI > |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220043048-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220118933-A |
| priorityDate | 2016-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 184.